MDHearing Volt vs Otofonix Groove

The MDHearing Volt is a budget-priced prescription hearing aid released in 2020, earning a B grade with a SoundScore of 3.0/5 in our lab testing. At $397, it sits in the lowest price tier for prescription devices, ranking #34 of 39 in its category. In our testing, the Volt showed a mixed performance profile with one standout strength: feedback handling scored an excellent 5.0/5, which is 0.28 points above the category average. This means users can expect minimal whistling or squealing during typical wear. However, speech performance was limited, with speech in quiet scoring 1.8/5 (1.65 points below average) and speech in noise at 1.0/5 (1.11 points below average). Own voice comfort was mixed at 2.6/5, roughly matching the category average. Music streaming capability was not functional in our testing, scoring 0.0/5—a significant limitation for users who want to stream audio from their phone. This is 2.76 points below the prescription hearing aid category average. The Volt may appeal to budget-conscious consumers who prioritize basic amplification and feedback-free wear over advanced speech enhancement or streaming features. Those seeking stronger speech performance in the same price range may want to consider alternatives like the RxEars Rxi, which scored 4.07/5 in our testing. The Volt's rechargeable battery and behind-the-ear design offer practical convenience, but its core sound performance reflects its entry-level positioning.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.